High risk of myelodysplastic syndrome and acute myeloid leukemia after177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy

6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial

(2015) J. Strosberg et al.   EUROPEAN JOURNAL OF CANCER

Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

(2015) Hendrik Bergsma et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)

(2015) M G Della Porta et al.   LEUKEMIA

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

(2014) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Hematological Toxicity of Combined177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up

(2014) Murali Kesavan et al.   NEUROENDOCRINOLOGY

Can peptide receptor radionuclide therapy be safely applied in florid bone metastases?

(2014) A. Sabet et al.   NUKLEARMEDIZIN-NUCLEAR MEDICINE

Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate

(2013) A. Sabet et al.   JOURNAL OF NUCLEAR MEDICINE

ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

(2012) Marianne Pavel et al.   NEUROENDOCRINOLOGY

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

(2011) Anna Imhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY